Lorecivivint, a Novel Intraarticular CDC‐like Kinase 2 and Dual‐Specificity Tyrosine Phosphorylation‐Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial

OBJECTIVE: To assess the safety and efficacy of a novel Wnt pathway modulator, lorecivivint (SM04690), for treating pain and inhibiting structural progression in moderately to severely symptomatic knee osteoarthritis (OA). METHODS: Subjects in this 52‐week, phase IIa, multicenter, randomized, double...

Descripción completa

Detalles Bibliográficos
Autores principales: Yazici, Yusuf, McAlindon, Timothy E., Gibofsky, Allan, Lane, Nancy E., Clauw, Daniel, Jones, Morgan, Bergfeld, John, Swearingen, Christopher J., DiFrancesco, Anita, Simsek, Ismail, Tambiah, Jeyanesh, Hochberg, Marc C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Osteoarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589351/
https://www.ncbi.nlm.nih.gov/pubmed/32432388
http://dx.doi.org/10.1002/art.41315

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589351/
https://www.ncbi.nlm.nih.gov/pubmed/32432388
http://dx.doi.org/10.1002/art.41315

Ejemplares similares